Harold M. Hastings
Long Island Jewish Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Harold M. Hastings.
The Journal of Urology | 1997
Eliot M. Rosen; Ansamma Joseph; Liang Jin; Yan Yao; Minh-Hang T. Chau; Alexander Fuchs; Leonard G. Gomella; Harold M. Hastings; Itzhak D. Goldberg; Gary H. Weiss
PURPOSEnWe previously reported increased titers of scatter factor in urine of 20 patients with transitional cell carcinoma of the bladder compared to noncancer and cancer control groups. Scatter factor was also found in bladder tumor extracts but the number of samples examined was too small for detailed analysis. We report a followup study of larger numbers of patients with transitional cell carcinoma and controls.nnnMATERIALS AND METHODSnThe scatter factor content of urine samples and bladder tissue extracts was measured by enzyme-linked immunosorbent assay. Values were normalized per milligram creatinine or tissue protein. Statistical analysis was performed using the Mann-Whitney U test or, for multiple comparisons, the Kruskal-Wallis H test.nnnRESULTSnPatients with transitional cell carcinoma of the bladder (52) had higher urinary scatter factor titers than did 24 normal subjects (p < 0.001) or 14 with benign prostatic hypertrophy (p < 0.001), 49 with prostate cancer (p < 0.001) and 13 with other genitourinary tract cancers (p < 0.01). Transitional cell carcinoma cases with clinicopathological evidence of disease had greater urinary scatter factor levels than those with no evidence of disease at urine sampling (p < 0.01). However, patients with transitional cell carcinomas in remission still had much greater urinary scatter factors than did normal subjects (p < 0.001). In contrast, patients with active prostate cancer had urinary scatter factor levels similar to those in remission. Patients with muscle invasive or high grade transitional cell carcinomas tended to have higher urinary scatter factor levels than patients with nonmuscle invasive or low grade tumors, respectively, but the differences were not significant. Greater levels of scatter factor were present in tissue extracts of muscle invasive transitional cell carcinomas than in nonmuscle invasive tumors (p < 0.001) or nontumor tissue (p < 0.02). Invasion was more closely related to tissue scatter factor content than tumor grade, since high grade noninvasive transitional cell carcinomas had a scatter factor content similar to that of low grade noninvasive transitional cell carcinomas.nnnCONCLUSIONSnThese studies suggest that scatter factor may be a marker of bladder cancer, urinary scatter factor titers tend to reflect disease activity and particularly high tissue titers of scatter factor are found in muscle invasive cancers. A larger prospective study will be necessary to determine the clinical significance of elevated scatter factor titers in transitional cell carcinoma of the bladder.
Proceedings of the Royal Society of London B: Biological Sciences | 1998
Steven J. Evans; Harold M. Hastings; Sachin Nangia; Joanne Chin; Michael Smolow; Obi Nwasokwa; Alan Garfinkel
Ventricular fibrillation is the major cause of sudden cardiac death, the leading cause of death in the industrialized world; however, the mechanisms for its onset are not well understood. To further understand the dynamics of fibrillation at and near its onset, we compared spatial and temporal variability of mean interactivation intervals in a stable canine model for ventricular fibrillation. Temporal variability was very small, suggesting that the relevant physiological parameters remained constant during our experiments. Spatial variability was usually significantly larger and appeared incompatible with the dynamics of a single, meandering spiral wave. This confirmed recent results that a single spiral wave cannot generate ventricular fibrillation. Thus the onset of fibrillation is a multistage process, with spiral–wave breakdown providing a crucial step in the quasi–periodic route to fibrillation.
Archive | 1995
Steven J. Evans; Scott L. Roth; Harold M. Hastings
Archive | 2008
Scott L. Roth; Edward Paul Harhen; Harold M. Hastings; Nicolas Heron
Archive | 2008
Harold M. Hastings; Scott L. Roth
Archive | 2006
Harold M. Hastings; Scott L. Roth
Archive | 2004
Scott L. Roth; Harold M. Hastings
Archive | 2010
Harold M. Hastings; Scott L. Roth
Archive | 2006
Harold M. Hastings; Scott L. Roth
Archive | 2009
Harold M. Hastings; Scott L. Roth